Drugs@FDA record for NDA 204630 – ProvayBlue (methylene blue injection), Provepharm SAS (2016)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · April 8, 2016

U.S. Food et al., 2016-04-08: FDA application record showing methylene blue injection approved as NDA 204630 on 8 April 2016 (original approval, submission classification 'Type 5 – New Formulation or New Manufacturer') for Provepharm SAS, with several generic applicants listed as therapeutically equivalent.

04/08/2016 ORIG-1 Approval Type 5 – New Formulation or New Manufacturer

U.S. Food et al., 2016-04-08: FDA application record showing methylene blue injection approved as NDA 204630 on 8 April 2016 (original approval, submission classification 'Type 5 – New Formulation or New Manufacturer') for Provepharm SAS, with several generic applicants listed as therapeutically equivalent. C14/F6 record field (Drugs@FDA application page; transcribed, not prose). Country: USA. Establishes: (1) the molecule is not protected – ANDAs from Chengdu Shuode (219550), Hikma (216959), Meitheal (217380) and others are listed as AP-equivalent to ProvayBlue; (2) the approved 2016 product is a NEW FORMULATION of a drug in use since the 19th century, which fits the 'cannot be patented' argument for the molecule but not for formulations. The Orange Book page for the same application prints 'Patent and Exclusivity Information' with no patent numbers in the extracted text; Google Patents refused automated access from this network, so no patent number is recorded here (see flag report). Also filed as MTI-03 (claims C1, C14). Study type: regulatory record.